# Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

> **NCT05482451** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **China Medical University Hospital** · enrollment: 10 (actual)

## Conditions studied

- Effect of Drug

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** all trans retinoic acid

## Key facts

- **NCT ID:** NCT05482451
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482451, "Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05482451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*